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Abstract
Background: Rheumatoid arthritis (RA) is an inflammatory autoimmune disease that causes chronic synovitis,
resulting in progressive joint destruction and functional disability and affects approximately 400,000 people in the
UK. This real-world study aimed to describe the characteristics, treatment patterns and clinical outcomes of patients
who received abatacept in UK clinical practice.
Methods: This was a multi-centre, retrospective, observational study of patients with RA treated with abatacept at
four UK centres between 01 January 2013 and 31 December 2017. Data were collected from medical records of
each patient from the index date (date of first bDMARD initiation) until the most recent visit, death or end of study
(31 December 2017).
Results: In total, 213 patients were included in the study. Patients received up to eight lines of therapy (LOTs).
Treatment with abatacept, or any other bDMARD, was associated with reductions in DAS28-ESR and DAS28-CRP
scores at 6 and 12 months. The distribution of EULAR responses (good/moderate/no response) tended to be more
favourable for patients when receiving abatacept than when receiving other bDMARDs (22.8%/41.3%/35.9% versus
16.6%/41.4%/42.1% at 6 months, and 27.9%/36.1%/36.1% versus 21.2%/34.5%/44.2% at 12 months). Patients
receiving abatacept at LOT1 (n = 68) spent significantly longer on treatment compared with patients receiving
other bDMARDs (53.4 vs. 17.4 months; p< 0.01); a similar trend was observed for LOT2. Among patients who
discontinued after 6 months, a greater proportion experienced infection requiring antibiotics when receiving other
bDMARDs compared to those receiving abatacept.
Conclusions: RA patients who received bDMARDs, including abatacept, experienced reduced disease activity.
When receiving abatacept as first or second line of therapy, patients persisted with treatment significantly longer
than those receiving other bDMARDs.
Keywords: Abatacept, Biologic, DMARD, Disease activity, Observational study, Rheumatoid arthritis, Time on
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Background
Rheumatoid arthritis (RA) is a systemic autoimmune dis-
ease driven by both pro-inflammatory cytokines and
pathogenic autoantibodies that causes chronic synovitis,
resulting in progressive joint destruction and functional
disability [1–5]. RA-driven inflammatory processes are
also associated with interstitial lung disease and cardio-
vascular disease, leading to increased disability and mor-
tality [1]. It is estimated that over 400,000 people in the
UK have RA [6, 7], and this progressive and often debili-
tating disease can have a detrimental effect on quality of
life for patients, their families, and carers [8, 9].
Whilst there is no cure for RA, current therapies aim
to slow disease progression by reducing inflammation
and minimising joint damage. National and international
treatment guidelines recommend treatment with bio-
logical DMARDs (bDMARDs), such as abatacept, after
failure of conventional synthetic disease-modifying anti-
rheumatic drugs (csDMARDs) when the treatment tar-
get is not achieved or poor prognostic factors are
present [10–12]. Positivity for rheumatoid factor (RF)
and/or anti-citrullinated protein-peptide antibodies
(ACPA) is a useful diagnostic and prognostic marker for
RA as they may affect treatment response, with some
evidence that the presence of these autoantibodies is as-
sociated with poorer outcomes [13–18].
International observational studies demonstrate the
impact of abatacept on patient outcomes [19], as well as
prognostic factors for abatacept retention [20] and dur-
ability [21, 22]. Others have found that abatacept per-
forms favourably in terms of treatment persistence when
compared to tumour necrosis factor inhibitors (TNFi)
[23] and other non-TNFi [24]. However, clinical effect-
iveness and treatment patterns of abatacept for treating
RA have not been well-studied in real-world routine
practice, notably in a UK population. Therefore, this
study aimed to investigate the characteristics of patients
who received abatacept in the UK real-world setting,
their treatment patterns and disease activity.
Methods
This study was a multi-centre, retrospective, observa-
tional chart review of patients with RA treated with aba-
tacept at four UK centres: University Hospital of Wales,
The Royal Wolverhampton NHS Trust, Hull University
Teaching Hospitals NHS Trust, Sheffield Teaching Hos-
pitals NHS Foundation Trust. The research window was
from 01 January 2013 to 31 December 2017. The index
date was defined as the date of first bDMARD initiation
(irrespective of line of therapy (LOT)). Data were col-
lected for each patient until the most recent visit (up
until 31 December 2017) or death.
The study received ethical approval form the Yorkshire
& The Humber - South Yorkshire Research Ethics
Committee (Reference: 18/YH/0412) and research per-
missions from the Health Research Authority (Reference:
242712).
Eligible patients were identified through screening of
medical records at the study centres. Patients were in-
cluded in the study if they met all the following criteria:
aged ≥18 years on index date (date of first bDMARD ini-
tiation); received abatacept for the treatment of RA at
any LOT within the research window (01 January 2013
to 31 December 2017); medical records contained at
least two of disease activity score for 28 joints - erythro-
cyte sedimentation rate (DAS28-ESR) or disease activity
score for 28 joints – C-reactive protein (DAS28-CRP)
scores as part of RA treatment monitoring: one on index
date and another score at 6 ± 3months and/or 12 ± 3
months following treatment initiation. Patients with pre-
clinical RA, including undifferentiated arthritis, and/or
with comorbid RA or other types of (non-rheumatoid)
arthritis were excluded from the study.
A bespoke electronic case report form (eCRF) was
used to record all study data. Data from each eligible pa-
tient were extracted from medical records and entered
into the eCRF by the investigator or their assigned staff
at each study centre. The eCRF allowed investigators to
remove patient identifiers and ensure only pseudo-
anonymised patient-level data were analysed. Built-in
validation checks were also used to facilitate accurate
and valid data entry. Data collection was entirely retro-
spective and did not involve any direct patient contact.
Baseline patient demographic and clinical characteris-
tics were analysed descriptively, where baseline was de-
fined as the index date (date of first bDMARD
initiation). Summary statistics (mean, standard deviation,
median and interquartile range [IQR]) were presented
for continuous variables, with counts, proportions,
and percentages presented for categorical variables.
Analyses were also stratified by positive and/or nega-
tive ACPA and RF status. Time on treatment was
summarised as a continuous variable and time-to-
event curves (based on time to treatment discontinu-
ation or end of follow up [EOFU]) were derived using
the Kaplan-Meier method. Log-rank and Wilcoxon
tests were used to ascertain statistically significant dif-
ferences in time on treatment between subgroups.
Changes in DAS28 scores were calculated from LOT
initiation: 6 month scores were calculated using the
recorded score closest to the end of month 6 and in-
cluded scores recorded between months 4 and 9; 12
months scores were calculated using the recorded
score closest to the end of month 12 and included
those recorded between months 10 and 15. Associa-
tions between change in DAS28 (ESR or CRP) score
and bDMARD were modelled using a linear mixed-
effects model.
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ACPA and/or RF status not
recorded (n = 98)
Demographics (at index date unless specified)
Age (years old)
Mean (SD) 55.2 (13.1) 56.1 (12.9) 46.2 (6.6) 54.6 (13.3) 54.0 (15.2) 55.5 (13.1)
Median (IQR) 55.4 (46.9–
64.6)
56.2 (48.3–64.1) 47.8 (43.9–48.8) 51.4 (45.1–63.5) 57.5 (43.6–67.0) 55.1 (48.0–64.7)
Sex
Female, n (%) 152 (71.4%) 54 (71.1%) a 10 (100.0%) 17 (77.3%) 66 (67.3%)
Weight (kg)
Mean (SD) 79.4 (17.8) 79.7 (18.7) 80.1 (12.6) 78.7 (16.0) 90.2 (23.0) 77.3 (16.1)
Median (IQR) 77.2 (65.8–
89.7)
76.2 (65.6–95.0) 79.4 (70.1–89.4) 71.9 (68.8–84.9) 86.2 (75.0–91.0) 76.8 (64.9–88.3)
SBP (mmHg)
Mean (SD) 134.8 (19.3) 131.5 (21.2) 129.7 (14.6) 145.3 (24.7) 143.8 (15.4) 135.0 (17.1)












Mean (SD) 78.7 (10.9) 77.2 (11.0) 70.7 (7.4) 73.1 (11.8) 85.1 (12.1) 80.0 (10.0)
Median (IQR) 78.0 (70.0–
86.0)




39 (18.3%) 14 (18.4%) 0 (0.0%) a a 21 (21.4%)
Past smoker – n
(%)
26 (12.2%) 15 (19.7%) 0 (0.0%) a a 7 (7.1%)
Never smoked – n
(%)
61 (28.6%) 20 (26.3%) a a 8 (36.4%) 25 (25.5%)
Unknown – n (%) 87 (40.8%) 27 (35.5%) a a 7 (31.8%) 45 (45.9%)
Year of RA diagnosis
≤2009– n (%) 39 (18.3%) a a a a 18 (18.4%)
2010 – n (%) 45 (21.1%) 16 (21.1%) a a a 22 (22.4%)
2011 – n (%) 66 (31.0%) 17 (22.4%) a a 6 (27.3%) 39 (39.8%)
2012 – n (%) 54 (25.4%) 26 (34.2%) a a 9 (40.9%) a
2013 – n (%) 9 (4.2%) a 0 (0.0%) a 0 (0.0%) a
RA duration at index date
Mean (SD) 7.0 (7.9) 6.4 (8.1) 8.7 (8.1) 5.4 (6.5) 5.7 (5.4) 7.7 (8.2)
Median (IQR) 3.9 (2.1–8.5) 3.3 (2.1–7.2) 4.6 (4.3–10.5) 2.2 (1.3–6.9) 3.8 (1.9–7.8) 5.1 (2.5–9.0)
Patient history (5 years prior to index date), n (%)
Myocardial
infarction
8 (3.8%) a 0 (0.0%) 0 (0.0%) 0 (0.0%) a
Other ischemic CV
disease
11 (5.2%) a 0 (0.0%) 0 (0.0%) a 5 (5.1%)
Stroke 5 (2.3%) a 0 (0.0%) 0 (0.0%) a a
Cancer 13 (6.1%) 6 (7.9%) 0 (0.0%) a a a
COPD 10 (4.7%) a 0 (0.0%) 0 (0.0%) a 6 (6.1%)
Hypertension 44 (20.7%) 14 (18.4%) a a 5 (22.7%) 20 (20.4%)
Asthma 30 (14.1%) 11 (14.5%) a a 5 (22.7%) 9 (9.2%)
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Results
In total, 213 patients met eligibility criteria and were in-
cluded in the study. The mean age of patients was 55.2
years and 71.4% of patients were female. The majority of
patients (70.4%) were diagnosed with RA prior to 2009
and the median (IQR) RA disease duration was 3.9 (2.1–
8.5) years (Table 1). The study population contained:
ACPA+/RF+, n = 76; ACPA+/RF-, n = 7; ACPA−/RF+ n
=10; ACPA−/RF-, n = 22; unknown RF/ACPA status, n=
98 (Table 1). Patients’ demographic and clinical charac-
teristics were also broadly comparable when stratified by
LOT and treatment received.
Patients received up to 8 LOTs (Fig. 1). Patients who
received abatacept in LOT1 usually did not receive any
further lines of treatment (n = 63, 92.6%). This was due
to patients reaching EOFU (n = 51, 81.0%), adverse
events (n = 5, 7.9%), disease progression (n = < 5), or
other reasons not otherwise stated (n = 5, 7.9%). Patients
receiving abatacept at LOT1 (n = 68) spent significantly
longer on treatment compared with patients receiving
other bDMARDs (median 53.4 vs. 17.4 months; p< 0.01)
(Fig. 2, Table 2). For patients receiving abatacept at
LOT1, 85.6, 70.9 and 70.9% of patients were still in re-
ceipt of abatacept at 12, 24 and 36 months, respectively,
compared with 63.4, 39.3 and 31.7% of patients receiving
other bDMARDs, respectively. A similar pattern was ob-
served at LOT2 (n = 59), with median time on treatment
of 40.1 vs 17.1 (p< 0.01) months, respectively.
The number of patients who discontinued bDMARD
treatment within 6 months and after 6 months of any
LOT initiation, stratified by LOT, are summarised in
Table 3. The proportion of patients receiving abatacept
and still on treatment at EOFU was greater for all LOTs
compared with patients who received other bDMARDs.
Greater proportions of patients who discontinued other
bDMARDs in LOTs 1–4 after 6 months tended to












ACPA and/or RF status not
recorded (n = 98)
Interstitial lung
disease
13 (6.1%) 7 (9.2%) a 0 (0.0%) a a
Diabetes 15 (7.0%) 8 (10.5%) 0 (0.0%) 0 (0.0%) a a
ACPA titre (U/ml)
n 119 76 a 10 22 a






2.2 (0.3–5.3) 0.0 (0.0–1.0) 51.0 (30.9–123.0)
RF titre (U/ml)
n 180 76 7 10 22 65




0.0 (0.0–11.6) 32.9 (21.8–90.8) 0.0 (0.0–6.8) 66.0 (27.0–100.0)
DAS28-ESR score
Mean (SD) 6.3 (1.0) 6.3 (0.9) 6.9 (0.9) 6.0 (0.9) 6.4 (0.8) 6.2 (1.2)
Median (IQR) 6.3 (5.7–7.0) 6.4 (5.7–7.0) 6.7 (6.1–7.4) 5.4 (5.4–7.0) 6.3 (6.0–6.9) 6.2 (5.4–6.7)
High – n (%) 89 (80.9%) 41 (80.4%) 7 (100.0%) a 17 (94.4%) 22 (75.9%)
Moderate – n (%) 20 (18.2%) 10 (19.6%) 0 (0.0%) a a 6 (20.7%)
Low – n (%) a 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) a
Remission – n (%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
DAS28-CRP score
Mean (SD) 5.5 (1.2) 5.8 (0.8) 6.4 (1.0) 5.3 (1.3) 6.0 (0.9) 5.2 (1.3)
Median (IQR) 5.5 (4.8–6.3) 5.7 (5.2–6.3) 6.0 (5.8–6.6) 5.5 (4.5–6.1) 6.1 (5.5–6.7) 5.1 (4.3–6.3)
High – n (%) 70 (51.9%) 27 (60.0%) a a 7 (70.0%) 29 (41.4%)
Moderate – n (%) 60 (44.4%) 18 (40.0%) 0 (0.0%) a a 36 (51.4%)
Low – n (%) a 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) a
Remission – n (%) a 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) a
ACPA Anti-citrullinated protein antibodies, CV Cardiovascular, COPD Chronic obstructive pulmonary disease, CRP C-reactive protein, CV Cardiovascular, DAS28
Disease activity score, DBP Diastolic blood pressure, ESR Erythrocyte sedimentation rate, IQR Interquartile range, RF Rheumatoid factor, SBP Systolic blood pressure,
SD Standard deviation
aCells suppressed due to small numbers
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Fig. 1 Sankey diagram depicting treatment sequencing for bDMARDs in patients with rheumatoid arthritis. bDMARD: biologic disease modifying
antirheumatic drug; LOT: line of therapy
Fig. 2 Time on treatment from LOT1 initiation stratified by abatacept vs other bDMARD therapy. Source: Henning et al. [25]
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experience infections requiring antibiotics, compared
with patients who discontinued abatacept. However, this
difference was not statistically significant, which may be
due to the low number of recorded infections requiring
antibiotics for patients receiving abatacept (Table 4).
Overall, treatment with abatacept or any other
bDMARD was associated with reductions in DAS28-ESR
and DAS28-CRP scores at 6 and 12months after any
LOT initiation, when adjusted for age and sex (Fig. 3,
Tables 5 and 6). At 6 months, there was a greater incre-
mental difference in DAS28-ESR scores between patients
receiving abatacept versus other bDMARDs (observed
for all ACPA and RF stratifications, with the exception
of RF- and ACPA−/RF- subgroups). For DAS28-CRP,
there was also a greater incremental difference in scores
between patients receiving abatacept versus other
bDMARDs (with the exception of RF- and ACPA+/RF-
subgroups). Statistical significance was observed for the
ACPA−/RF+ subgroup (LG mean: -2.22; 95% CI: − 3.64,-
0.81; p=0.01). At 12 months, similar trends were ob-
served for DAS28-ESR and DAS28-CRP scores, with
statistical significance observed for the overall cohort
(LS mean: -0.56; 95% CI: − 1.04,-0.07; p=0.03) and the
RF+ subgroup (LS mean: -0.49; 95% CI: − 0.95,-0.03; p=
0.04), respectively.
The distribution of EULAR responses (good/moder-
ate/no response) tended to be more favourable for pa-
tients receiving abatacept than when receiving other
bDMARDs at any LOT (22.8%/41.3%/35.9% versus
16.6%/41.4%/42.1% at 6 months, and 27.9%/36.1%/36.1%
versus 21.2%/34.5%/44.2% at 12 months) (see Additional
file 1: Table 1).
Discussion
This retrospective chart review study included data from
213 RA patients treated with abatacept at any LOT
across four NHS centres in the UK from 2013 to 2017.
The mean age of included patients was 55.2 years and
patients were predominantly female (71.4%). This aligns
with the characteristics of the overall UK RA population,
with more women affected by RA than men and diagno-
sis typically occurring between 40 and 60 years of age
Table 2 Time on treatment from LOT1 initiation, abatacept compared to other bDMARD therapy
bDMARD therapy Median (months) R-Mean (months) Max Follow Up (months) Month 12 (%) Month 24 (%) Month 36 (%) P-value
Abatacept 53.4 41.2 53.4 85.6% 70.9% 70.9% W:< 0.01*
LR:< 0.01*
Other 17.4 31.4 139.9 63.4% 39.3% 31.7%
bDMARD Biologic disease-modifying antirheumatic drug, LOT Line of therapy, LR Log-Rank, R-Mean Restricted-mean (mean survival restricted at maximum follow-
up within the cohort), W Wilcoxon
* Denotes significance at p-value < 0.05









Time to discontinuation, months
Mean (SD)
Within 6months of LOT initiation After 6 months of LOT initiation
All patients (n = 213)
LOT1 213 51 (23.9%) 29.4 (31.8) 36 (16.9%) 126 (59.2%)
LOT2 150 42 (28.0%) 20.2 (20.4) 29 (19.3%) 79 (52.7%)
LOT3 101 43 (42.6%) 16.7 (16.2) 20 (19.8%) 38 (37.6%)
LOT4 48 18 (37.5%) 22.2 (25.1) 11 (22.9%) 19 (39.6%)
Received abatacept
LOT1 68 51 (75.0%) 13.0 (12.4) 5 (7.4%) 12 (17.6%)
LOT2 59 40 (67.8%) 12.7 (10.7) 7 (11.9%) 12 (20.3%)
LOT3 50 38 (76.0%) 12.1 (6.9) 4 (8.0%) 8 (16.0%)
LOT4 23 11 (47.8%) 10.7 (11.0) 5 (21.7%) 7 (30.4%)
Received other bDMARD
LOT1 145 0 (0.0%) 31.4 (32.8) 31 (21.4%) 114 (78.6%)
LOT2 91 2 (2.2%) 21.8 (21.6) 22 (24.2%) 67 (73.6%)
LOT3 51 5 (9.8%) 17.9 (17.7) 16 (31.4%) 30 (58.8%)
LOT4 25 7 (28.0%) 29.9 (29.0) 6 (24.0%) 12 (48.0%)
bDMARD Biologic disease-modifying antirheumatic drugs, EOFU End of follow-up, LOT Line of therapy. lOTs 5–8 removed due to a high proportion requiring small
number suppression
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[7]. In this study, the median (IQR) duration of RA be-
fore starting bDMARD therapy was 3.9 (2.1–8.5) years.
Disease duration and number of prior DMARDs can
affect treatment response in patients with established
RA [26], and delayed start of disease-modifying therapy
is associated with reduced disease control and poorer
long-term outcomes [27, 28].
Of those patients with known ACPA and RF status (n
= 115), 66.1% were ACPA+/RF+, 19.1% were ACPA
−/RF-, 8.7% were ACPA−/RF+, and 6.1% were ACPA+/
RF-. However, there was a large proportion of patients
with missing ACPA and RF data (n = 94/213 and n =
33/213, respectively). This may be explained by the fact
that ACPA was only introduced into the updated ACR/
EULAR Rheumatoid Arthritis Classification Criteria in
2010 [29] but the majority of patients in this study
(70.4%) were diagnosed with RA prior to 2009. It should
also be noted that investigations of ACPA and RF are
also recommended by NICE [30].
Changes in DAS28 scores observed in this study
exceeded the 1.2- threshold considered to be clinically
significant changes over time in patients with RA [31,
32]. In particular, RF negative status was associated with
a trend towards lower incremental differences in DAS28
score when receiving abatacept. Published literature in-
dicates that both RF and ACPA positivity are important
Table 4 Infections requiring antibiotics for patients who discontinued treatment after 6 months of LOT initiation























a 27 (23.7%) a 18 (26.9%) a 13 (43.3%) a 5 (41.7%)
Discontinued
treatment (%)
a 27 (23.7%) a 18 (26.9%) 0 (0.0%) 12 (40.0%) a 5 (41.7%)
LOT Line of therapy
aCells suppressed due to small numbers
Fig. 3 Difference in DAS28-ESR and -CRP scores at 6 and 12 months after LOT initiation. ACPA: anti-citrullinated protein antibodies; bDMARD:
biologic disease modifying antirheumatic drug; CI: confidence interval; CRP: C-reactive protein; DAS: disease activity score; ESR: erythrocyte
sedimentation rate; LOT: line of therapy; RF: rheumatoid factor. Note: Where applicable, error bars have been capped from −4 to 1
for presentability
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predictors of remission outcomes. For abatacept, ACPA
positive status has been associated with better clinical
response independent from disease activity [33, 34]. The
distribution of EULAR responses further supports the
observation of greater improvement in DAS28-ESR
scores in patients whilst receiving abatacept.
Patients receiving abatacept spent significantly longer
on treatment than patients receiving other bDMARDs
(median 53.4 months compared with 17.4 months from
LOT1 initiation, respectively, p< 0.01). A similar pattern
was observed at LOT2, with median time on treat-
ment of 40.1 vs 17.1 months, respectively. This obser-
vation has also been reported in other studies where
treatment persistence and durability were highest for
abatacept initiators. In other real-world studies, abata-
cept retention was high, particularly when abatacept
was used in earlier lines of treatment [24]. Use of
abatacept has also been found to impact the overall
pattern of ACPA fine specificities over time [35]. This
longer duration of treatment adherence is both bene-
ficial in terms of clinical effectiveness but also poten-
tially for patients’ quality of life and that of their
family and carers [8, 9].
In both clinical trials and observational studies, abata-
cept was associated with a lower risk of hospitalised in-
fection compared with other bDMARDs [36, 37].
Indeed, an observational study of abatacept compared
with other bDMARDs reported a significant reduction in
infections requiring hospitalisation in patients receiving
abatacept (HR: 0.37 (95% CI: 0.18–0.75) [38]. In the
head-to-head Abatacept versus Adalimumab Compari-
son in Biologic-Naive RA Subjects with Background
Methotrexate (AMPLE) phase 3b trial, serious infections
were experienced in 12 (3.8%) and 19 (5.8%) patients, for
abatacept versus adalimumab respectively; the majority
of these infections resulted in hospitalisation (12 and 18)
[39]. In this study, a greater proportion of patients re-
ceiving other bDMARDs in LOTs 1–4 experienced in-
fection requiring antibiotics compared with those
receiving abatacept when discontinuation was stratified
by therapy (i.e. abatacept or other bDMARDs), specific-
ally patients who have discontinued after 6 months from
treatment initiation. These findings may indicate that
treatment with abatacept is potentially associated with
lower rates of infections given that there should be no
difference in the recording of antibiotic use by type of




Abatacept Other bDMARD Incremental difference
Cohort (n) Mean 95% CI Cohort (n) Mean 95% CI LS Mean 95% CI P value
DAS28-ESR
All patients 92 −1.59 −1.95,-1.23 145 −1.56 − 1.87,-1.24 − 0.04 − 0.45,0.38 0.86
ACPA+ 48 −1.58 −2.09,-1.06 60 − 1.21 −1.71,-0.71 −0.37 − 0.97,0.24 0.24
ACPA- 20 −2.03 −2.96,-1.09 30 −1.92 −2.79,-1.05 − 0.11 − 0.94,0.73 0.81
RF+ 65 −1.57 −2.00,-1.15 94 −1.39 − 1.78,-1.00 −0.19 −0.69,0.32 0.47
RF- 21 −1.73 −2.59,-0.86 34 −2.01 − 2.83,-1.18 0.28 −0.51,1.08 0.49
ACPA+/RF+ 45 −1.58 −2.10,-1.05 47 − 1.10 − 1.61,-0.59 −0.48 − 1.11,0.15 0.14
ACPA+/RF- a −2.59 −36.06,30.88 a −2.35 − 54.75,50.05 −0.24 −5.27,4.79 0.93
ACPA−/RF+ a −2.55 −4.73,-0.37 6 −1.28 −3.22,0.66 − 1.27 − 3.14,0.60 0.22
ACPA−/RF- 16 −1.88 −2.82,-0.93 24 −2.02 −2.91,-1.12 0.14 −0.76,1.04 0.76
DAS28-CRP
All patients 116 −1.55 − 1.82,-1.28 106 −1.39 − 1.68,-1.09 −0.16 − 0.50,0.18 0.36
ACPA+ 48 −1.49 − 1.94,-1.05 42 −1.20 − 1.71,-0.69 −0.29 − 0.83,0.24 0.28
ACPA- 11 −1.28 −2.22,-0.35 21 −1.14 −1.88,-0.40 −0.14 − 1.22,0.93 0.80
RF+ 87 −1.66 −1.97,-1.35 69 −1.43 − 1.80,-1.06 − 0.23 − 0.64,0.18 0.27
RF- 17 −1.25 −2.04,-0.47 25 −1.48 −2.21,-0.76 0.23 −0.67,1.13 0.62
ACPA+/RF+ 44 −1.50 −1.94,-1.06 38 −1.04 − 1.55,-0.53 −0.46 −1.02,0.11 0.12
ACPA+/RF- a −2.06 −13.11,9.00 a −2.80 −19.06,13.46 0.74 −2.47,3.96 0.69
ACPA−/RF+ a −3.10 −4.32,-1.89 6 −0.88 −1.97,0.22 −2.22 − 3.64,-0.81 0.01
ACPA−/RF- 6 0.18 −1.02,1.38 15 −1.11 −1.94,-0.29 1.30 −0.08,2.67 0.07
bDMARD Biologic disease-modifying antirheumatic drugs, CI Confidence interval, CRP c-reactive protein, DAS Disease activity score, ESR Erythrocyte sedimentation
rate; n is the number of patients with a DAS score recorded at LOT initiation and at 6 months
aCells suppressed due to small numbers
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bDMARD therapy. Routine use of biologic therapies for
RA that are associated with a lower risk of infections re-
quiring antibiotics may benefit the implementation and
success of national antimicrobial resistance (AMR) strat-
egies; AMR is a complex and significant public health
concern and existing national action plans aim to reduce
the need for and use of antimicrobials [40]. However,
the apparent association between infections requiring
antibiotics and bDMARDS requires further investigation
with larger study samples and more recent practice may
account for data from the wider RA population.
There are several methodological limitations in this
study. As the study was a retrospective chart review, it
may have been subject to incomplete or inaccurate ori-
ginal data entry in the medical records, as well as similar
issues during study data collection using the eCRF. A
further limitation of this study is the extent of missing
data (see Additional file 1: Tables 2 and 3). Whilst
changes to clinical practice may account for some miss-
ing data (e.g. APCA status), incomplete eCRFs also re-
stricted some subgroup analyses. The study was limited
to four UK study centres with limited geographical
spread, and thus the applicability of the findings to the
wider UK population is unknown. The sample size for
this study is also relatively modest, as abatacept has a
relatively small secondary care market share across
rheumatology specialities [41]. This is partly due to the
specific clinical recommendations for use of abatacept in
the UK [42, 43], as well as NHS England’s commission-
ing framework which aims to initiate 90% of new pa-
tients on the best value biological medicine within 3
months of a biosimilar medicine being launched [44].
However, abatacept is considered to be cost-effective for
patients with poor prognosis, with clear benefits in
health-related quality of life [45]. In addition, there is a
channelling bias associated with the study due to the
preferential prescribing of abatacept, partly due to its
favourable safety profile. The design of this study may
have limited the analysis of treatment discontinuation
and pathways. For example, in Fig. 3, discontinuation
events whilst receiving abatacept were clustered within
the first 24 months following treatment initiation,
whereas discontinuation events were spread across the
follow-up period whilst receiving other bDMARDs; this
is also represented in Table 4. This suggests that if pa-
tients can tolerate abatacept in the short-term, their




Abatacept Other bDMARD Incremental difference
Cohort (n) Mean 95% CI Cohort (n) Mean 95% CI LS Mean 95% CI P value
DAS28-ESR
All patients 61 −1.98 −2.41,-1.55 113 −1.42 − 1.76,-1.08 − 0.56 − 1.04,-0.07 0.03
ACPA+ 33 −1.84 −2.44,-1.23 46 −1.51 −2.05,-0.97 − 0.33 − 1.04,0.38 0.37
ACPA- 11 −2.44 − 3.53,-1.35 24 −1.79 −2.71,-0.88 −0.64 − 1.70,0.41 0.23
RF+ 42 −1.99 −2.51,-1.46 74 −1.43 −1.85,-1.01 −0.56 − 1.16,0.05 0.07
RF- 14 −1.90 −2.88,-0.92 28 −1.77 −2.62,-0.93 −0.12 − 1.04,0.79 0.80
ACPA+/RF+ 31 −1.83 −2.46,-1.21 42 −1.46 −2.02,-0.90 −0.37 −1.12,0.38 0.33
ACPA+/RF- a −2.75 −28.19,22.70 a −1.46 −59.19,56.28 −1.29 −6.91,4.33 0.67
ACPA−/RF+ a −2.21 −4.91,0.49 6 −0.91 −2.87,1.06 −1.30 −3.75,1.14 0.32
ACPA−/RF- 9 −2.30 −3.41,-1.18 18 −1.89 −2.84,-0.94 −0.41 − 1.55,0.74 0.49
DAS28-CRP
All patients 91 −1.86 −2.16,-1.56 90 −1.50 − 1.80,-1.19 −0.37 − 0.75,0.01 0.06
ACPA+ 35 −1.79 −2.30,-1.28 33 −1.52 −2.07,-0.98 −0.26 −0.88,0.35 0.40
ACPA- 9 − 1.85 −2.88,-0.83 16 −1.28 −2.10,-0.45 −0.58 − 1.79,0.64 0.36
RF+ 65 −2.02 − 2.38,-1.67 57 −1.53 −1.92,-1.14 −0.49 −0.95,-0.03 0.04
RF- 14 −1.58 −2.44,-0.72 21 −1.66 −2.42,−0.90 0.08 -0.90,1.07 0.87
ACPA+/RF+ 33 −1.79 −2.29,-1.28 31 −1.39 − 1.93,-0.84 − 0.40 − 1.03,0.24 0.22
ACPA+/RF- a −2.71 −13.76,8.35 a −2.73 −15.73,10.28 0.02 −3.62,3.66 0.99
ACPA−/RF+ a −2.28 − 3.49,-1.08 a −1.26 −2.77,0.26 −1.03 − 2.60,0.55 0.23
ACPA−/RF- a −1.23 −2.71,0.25 12 −1.15 −2.05,-0.24 −0.08 −1.74,1.57 0.92
bDMARD Biologic disease-modifying antirheumatic drugs, CI Confidence interval, CRP c-reactive protein, DAS Disease activity score, ESR Erythrocyte sedimentation
rate, n Is the number of patients with a DAS score recorded at LOT initiation and at 12 months
aCells suppressed due to small numbers
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longer-term tolerability was also positive. However, as
patients were only eligible for study inclusion if they re-
ceived abatacept during the study period, any prior
bDMARD therapies received in the lookback period
would have had to be discontinued, by definition. This
ultimately resulted in patients being more likely to reach
EOFU when receiving abatacept. Finally, it should be
noted that there was an unequal distribution of patients
from each of the four centres due to their capacity; eli-
gible patients were randomised by centre.
Conclusions
This study found clinical benefits associated with the use
of abatacept, related to treatment persistence, durability
and risk-benefit profile. These findings, along with the
literature discussed, support recommendations in the
NHS Long Term Plan to keep patient care close to or at
home where possible [46]. At the time of writing, the
COVID-19 pandemic is ongoing with unprecedented
pressures across the entire health care system. The
rheumatology community is working to optimise disease
management strategies and transition to telehealth [47].
Early research suggests the risk of serious complications
from COVID-19 is not increased for patients treated
with bDMARDs or tsDMARDs [48]. However, preventa-
tive withdrawal of these treatments, which may occur at
the time of COVID-19 symptom onset, should be
avoided due to the increased risk of relapse and morbid-
ity [48]. Future research should consider how abatacept
and other bDMARDs are used in RA management dur-
ing and after the pandemic.
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